Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Acceleron Pharma

Bristol Myers (BMY) and Acceleron received FDA nod for the label expansion of Reblozyl for MDS patients who require RBC transfusions, failing an erythropoiesis stimulating agent.

Bristol Myers/Acceleron's Reblozyl Label Expansion Gets FDA Nod

Celgene

Reblozyl recently became the first treatment for adults with lower-risk myelodysplastic syndromes.

Former Celgene Drug Earns a Key Approval for Bristol Myers Squibb

Bristol-Myers Squibb: A Great Buy After The Pullback

Avid Technology

DaVita

eBay

TEGNA

Dodge the COVID-19 pandemic by investing in these high earnings yield stocks.

Coronavirus-Led Volatility Rises: 5 High Earnings Yield Picks

Amcor Plc

Rocky Brands

Top Ranked Income Stocks to Buy for April 2nd

Gilead Sciences

Teladoc

With the coronavirus pandemic pushing stock prices to historic lows, there are plenty of promising companies to invest in today.

Top 3 Healthcare Stocks to Buy Right Now

Bristol-Myers Squibb (BMY) closed the most recent trading day at $54.86, moving -1.58% from the previous trading session.

Bristol-Myers Squibb (BMY) Stock Moves -1.58%: What You Should Know

Bristol Myers (BMY) and bluebird file a biologics license application to the FDA seeking approval of idecabtagene vicleucel for heavily pre-treated patients with multiple myeloma. Stock gains.

Bristol Myers, bluebird Submit BLA for Myeloma Drug to FDA

Eli Lilly

Moderna

Vertex Pharmaceuticals

Postponed clinical trials might mean a longer time-to-market for certain drugs.

Do Clinical Trial Delays Mean Trouble for Pharmaceutical Stocks?

Johnson & Johnson

Based on historical performance, Johnson & Johnson (NYSE: JNJ) appears to be less attractive compared to Bristol-Myers Squibb in the current crisis. The current coronavirus crisis will likely impact pharmaceutical companies on two fronts, 1.

Is Johnson & Johnson A Better Bet Compared To Bristol-Myers Squibb After 15% Decline?

Abbott Labs

AstraZeneca

One thing has become increasingly obvious as the weeks have passed since the coronavirus threat entered the daily lexicon.

Why Big Pharmaceutical Stocks May Be the Best Place for Worried Investors Now

Genfit - ADR

Intercept Pharma

Madrigal Pharmaceuticals

Novartis

PTC Therapeutics

Roche Holding AG

The U.S. Food and Drug Administration is scheduled to make decisions on five therapies in the second quarter, and the one that could make the biggest impact on the company and its shares belongs to Intercept Pharmaceuticals Inc.

FDA Decisions on 5 Drugs Expected in 2nd Quarter

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes?

Are You Looking for a High-Growth Dividend Stock? Bristol-Myers Squibb (BMY) Could Be a Great Choice

AbbVie

Amgen

Biogen

iShares Nasdaq Biotechnology ETF

Pfizer

SPDR S&P Biotech ETF

Drug developers took center stage as the world looks to these companies to deliver an answer to COVID-19.

4 Reasons Drug Stocks Are a Buy Right Now

Intuitive Surgical

Profitable. Great revenue and earnings growth.

My Top Healthcare Stocks to Buy in the Market Crash

Apple

Amazon

Cisco Systems

Ford Motor Company

Alphabet

Microsoft

Oracle

As the U.S. economy starts to shut down, cash is king. It is obvious how important this is when airlines need billions of dollars of aid from the government.

The 10 American Companies With the Most Cash

Sanofi

Pipeline and products at these three pharmaceutical companies mean long-term revenue growth once current market turmoil has passed.

My Top 3 Drug Stocks to Buy in the Market Crash

The FDA approves Bristol Myers' (BMY) Zeposia for the treatment of adults with relapsing forms of multiple sclerosis.

Bristol Myers (BMY) Clinches FDA Nod for MS Drug Zeposia

Bristol-Myers Squibb’s (NYSE: BMY) cardiovascular drug sales have surged 326% from $1.9 billion in 2015 to $7.9 billion in 2019, with the massive success of its anti-coagulant, Eliquis. The drug has seen increased acceptance among physicians, resulting in market share gains.

What’s Behind 300% Jump In Bristol-Myers Squibb’s Cardiovascular Drugs Sales In The Last 4 Years?

Merck

Mylan

Several pharma & biotech companies announce their plan to fight coronavirus pandemic and state anticipated unfavorable impact of the outbreak on their business.

Pharma, Biotech Players Step Up Efforts Against Coronavirus

Alexion Pharma

Bargain prices and tremendous growth prospects make these stocks really attractive.

3 Dirt-Cheap Healthcare Stocks to Buy Right Now

Bristol-Myers Squibb Company (NYSE: BMY) shares are trading higher after the company announced the FDA has approved ZEPOSIA, its new oral treatment for relapsing forms of multiple sclerosis.

Why Bristol-Myers Squibb's Stock is Trading Higher Today

Shares of Bristol Myers Squibb stock popped Thursday after the pharmaceutical company grabbed U.S. approval for a key multiple sclerosis treatment, ozanimod.

How Bristol Myers' New MS Drug Has A Leg-Up On A Rival From Novartis

But the big drugmaker will delay its commercial launch due to the COVID-19 pandemic.

Bristol Myers Squibb's Multiple Sclerosis Drug, a Potential Blockbuster, Wins FDA Approval

As a Magic 8-ball might say, "Signs point to yes."

News for Bristol-Myers Stock (BMY)